Health & Personal Care
HIGH
FDA DRUG
51,320 Belsomra Tablets Recalled for Delayed Dissolution Risk — Check Your Lot Numbers
Merck Sharp & Dohme LLC recalled 51,320 cartons of Belsomra (suvorexant) tablets after identifying a risk of delayed dissolution. This defect can delay the release of the drug, hindering sleep onset. Consumers and healthcare providers should stop using the product immediately and contact the company for guidance.
Belsomra
Failed Dissolution